Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINGSIDE phase 2/3 study of AL102 in advanced desmoid tumors
MOH_2021-08-09_009948Phase 3Active, not recruiting
- Sponsor
- Ayala Pharmaceuticals, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varegacestat in aggressive fibromatosis (AF) (5 arms), sponsored by Ayala Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability of AL102 in Part A and Effect of AL102 on disease progression in Part B. Started Jul 2021; status: active, not recruiting.
02
Drugs
varegacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on MOH_2021-08-09_009948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-09_009948.